Abstract
The development of new orally administered anticoagulants, such as dabigatran, rivaroxaban, and apixaban, in the past few years has focused on avoiding some of the drawbacks associated with warfarin. This work aims to illustrate the main features of the most commonly used new oral anticoagulants, reviewing the current literature on the management of patients taking these drugs and needing oral and implant surgery, and discussing the currently proposed related guidelines.
Keywords:
Apixaban; Dabigatran; Oral anticoagulants; Oral surgery; Rivaroxaban.
MeSH terms
-
Administration, Oral
-
Anticoagulants / administration & dosage*
-
Anticoagulants / adverse effects
-
Antithrombins / administration & dosage*
-
Antithrombins / adverse effects
-
Dabigatran / administration & dosage
-
Dabigatran / adverse effects
-
Dental Care for Chronically Ill*
-
Factor Xa Inhibitors / administration & dosage*
-
Factor Xa Inhibitors / adverse effects
-
Humans
-
Oral Hemorrhage / chemically induced*
-
Oral Hemorrhage / prevention & control*
-
Oral Surgical Procedures*
-
Pyrazoles / administration & dosage
-
Pyrazoles / adverse effects
-
Pyridones / administration & dosage
-
Pyridones / adverse effects
-
Rivaroxaban / administration & dosage
-
Rivaroxaban / adverse effects
-
Warfarin / administration & dosage
-
Warfarin / adverse effects
Substances
-
Anticoagulants
-
Antithrombins
-
Factor Xa Inhibitors
-
Pyrazoles
-
Pyridones
-
apixaban
-
Warfarin
-
Rivaroxaban
-
Dabigatran